SHANDONG KEYUAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.25 CNY | -1.36% |
|
-2.64% | -31.70% |
| Sales 2022 | 443M 61M 4.81B | Sales 2023 | 448M 61.65M 4.86B | Capitalization | 3.69B 508M 40.03B |
|---|---|---|---|---|---|
| Net income 2022 | 91M 12.53M 988M | Net income 2023 | 77M 10.61M 836M | EV / Sales 2022 * | - |
| Net cash position 2022 | 149M 20.52M 1.62B | Net cash position 2023 | 686M 94.49M 7.45B | EV / Sales 2023 | 6.7 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
44.8
x | Employees | 624 |
| Yield 2022 * |
-
| Yield 2023 |
0.88% | Free-Float | 30.46% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.36% | ||
| 1 week | -2.64% | ||
| Current month | -8.61% | ||
| 1 month | -14.05% | ||
| 3 months | -29.61% | ||
| 6 months | -31.21% | ||
| Current year | -31.70% |
1 week
23.19
24.00
1 month
22.0027.50
Current year
19.5836.66
1 year
19.5863.99
3 years
19.5863.99
5 years
19.5863.99
10 years
19.5863.99
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Sheng Jiang
CEO | Chief Executive Officer | 50 | 15/05/23 |
Ji Lan Wang
DFI | Director of Finance/CFO | 58 | 31/07/03 |
Li Jun Lun
CHM | Chairman | 61 | 30/04/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Ming Shen
BRD | Director/Board Member | 65 | 22/04/19 |
Xiao Hong Zou
BRD | Director/Board Member | 65 | 05/09/15 |
Hai Ying Zheng
BRD | Director/Board Member | 61 | 22/04/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/24 | 23.25 | -1.36% | 839,053 |
| 18/06/24 | 23.57 | +0.34% | 816,500 |
| 17/06/24 | 23.49 | -0.80% | 629,400 |
| 14/06/24 | 23.68 | -0.29% | 818,936 |
| 13/06/24 | 23.75 | -0.54% | 889,903 |
End-of-day quote Shenzhen S.E., June 18, 2024
More quotes
Shandong Keyuan Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical APIs and their preparation products. The Company's main products include gliclazide, metformin hydrochloride, ropivacaine hydrochloride and others. The Company's products are used in hypoglycemic, anesthetic, cardiovascular and psychiatric diseases. The Company conducts its operations mainly in the domestic market.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -31.70% | 347M | |
| +52.93% | 803B | |
| +41.25% | 631B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.72% | 243B | |
| +2.17% | 228B | |
| +10.27% | 217B | |
| +6.24% | 164B |
- Stock Market
- Equities
- 301281 Stock
